−$0.31 (0.98%) At close $31.33 · Today
☾After Hours −$0.06 (0.21%) Nov 3, 7:59 PM ET
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Latest: IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates (Zacks Investment Research)
From news headlines · Not investment advice
Latest: IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates (Zacks Investment Research)
No confirmed cause yet: the newest headline naming the stock.
Last check 7:30 PM ET
Headlines open the publisher's site.Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about IDYA?
Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue EstimatesIDEAYA Biosciences reported a Q3 loss of $1.22 per share, beating the consensus estimate of $1.26 loss by 3.18%. The company posted revenues of $10.24 million, surpassing consensus by 14.69%, though this represents a significant decline from $207.83 million in the year-ago quarter. The stock has underperformed the S&P 500 by 18.7% year-to-date and carries a Zacks Rank #3 (Hold) rating.
Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?IDEAYA Biosciences is expected to report a quarterly loss of $1.26 per share with revenues of $8.93 million for Q3 2026, representing significant year-over-year declines. However, the company has a positive Earnings ESP of +1.50% combined with a Zacks Rank #3 (Hold), suggesting it will likely beat consensus EPS estimates. The company has only beaten estimates once in the last four quarters.
Headlines open the publisher's site.
$IDYA filed an 8-K with results (Item 2.02) at 8:04 AM ET on Tue, Nov 3.
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›
